- Home
- BSX
as 03-25-2025 11:31am EST
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 129.7B | IPO Year: | 1992 |
| Target Price: | $107.23 | AVG Volume (30 days): | 8.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.25 | EPS Growth: | 16.82 |
| 52 Week Low/High: | $66.80 - $107.17 | Next Earning Date: | 04-23-2025 |
| Revenue: | $16,747,000,000 | Revenue Growth: | 17.61% |
| Revenue Growth (this year): | 15.51% | Revenue Growth (next year): | 10.31% |
Stock Insider Trading Activity of Boston Scientific Corporation (BSX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Brown Vance R | BSX | SVP, GC and Corp. Secretary | Mar 21 '25 | Sell | $100.85 | 4,826 | $486,702.10 | 41,019 | |
| Woodworth Emily | BSX | SVP, Global Controller and CAO | Mar 3 '25 | Sell | $104.80 | 7,631 | $800,896.51 | 914 | |
| Woodworth Emily | BSX | SVP, Global Controller and CAO | Feb 28 '25 | Sell | $101.13 | 9,887 | $999,872.31 | 914 | |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Feb 24 '25 | Sell | $104.13 | 7,363 | $766,920.75 | 25,766 | |
| Zane Ellen M | BSX | Director | Feb 24 '25 | Sell | $104.23 | 13,586 | $1,416,133.99 | 34,944 | |
| Brown Vance R | BSX | SVP, GC and Corp. Secretary | Feb 21 '25 | Sell | $104.64 | 4,826 | $504,992.64 | 41,019 | |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Feb 19 '25 | Sell | $105.35 | 1,510 | $159,078.50 | 25,766 | |
| Brennan Daniel J. | BSX | EVP and CFO | Feb 18 '25 | Sell | $104.66 | 84,863 | $8,919,295.52 | 225,808 | |
| Sorenson John Bradley | BSX | EVP, Global Operations | Feb 18 '25 | Sell | $104.80 | 5,960 | $624,860.60 | 20,991 | |
| Sorenson John Bradley | BSX | EVP, Global Operations | Feb 13 '25 | Sell | $106.31 | 1,201 | $127,678.31 | 20,991 |
Latest Boston Scientific Corporation News
BSX Breaking Stock News: Dive into BSX Ticker-Specific Updates for Smart Investing
Zacks
a day ago
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic
Zacks
2 days ago
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider
Zacks
2 days ago
Fed's Stagflation Fears Weigh, Yet Growth Factors Make BSX Stock a Buy
Zacks
2 days ago
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?
Zacks
2 days ago
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues
Zacks
2 days ago
GEHC Stock Falls Despite New Launch to Boost Breast Cancer Diagnosis
Zacks
2 days ago
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
Zacks
2 days ago
Here's Why You Should Hold GEHC Stock in Your Portfolio for Now
Compare BSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BSX Boston Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.